

Q&A

- Please submit all questions concerning webinar content through the Q&A panel.
- Reminder:
- If you have participants watching this webinar at your site, please collect their names and emails.
 - We will be distributing a Q&A document in about one week. This document will fully answer questions asked during the webinar and will contain any corrections that we may discover after the webinar.

N4ACCR





Agenda • Overview • Collaborative Stage Data Collection System • Treatment





Key Statistics Estimated new cases and deaths from throat cancer (including cancers of the larynx) in the United States in 2012 New Cases 13, 510 Deaths 2,330


Risk Factors • Alcohol • Tobacco • HPV infection





































• Epithelial - Squamous Cell Carcinoma - Basaloid squamoid carcinoma - Small cell carcinoma • Non-epithelial - Lymphoma, sarcoma, melanoma









































Distant Metastasis Distant metastasis is relatively uncommon at diagnosis Lung Bone Liver Distant Metastasis AJCC Stage IV IVA moderately advance local/regional disease IVB very advanced local/regional disease IVC Distant metastasis

Coding Primary Site

- 1. Tumor Board
 - a. Specialty
 - b. General
- 2. Staging physician's site assignment
 - a. AJCC staging form
 - b. TNM statement in medical record

NAACCR

Coding Primary Site

3. If neither 1 or 2 available, based on whether tumor was resected

NAACCR

Coding Primary Site

- 4. If total resection of primary tumor was done, code based on:
 - a. Operative report surgeon's statement
 - b. Final diagnosis on pathology report

NAACCI

Coding Primary Site

- 5. If total resection was NOT done code based on:
 - a. Endoscopy
 - b. Radiation oncologist
 - c. Diagnosing physician
 - d. Primary care physician

Continued on next slide

NAACCI

Coding Primary Site


- e. Other physician
- f. Diagnostic imaging
- g. Physician statement based on clinical examination


NAACCR²

Default Site Codes

- Point of origin cannot be determined
 - C02.8 Overlapping lesion of tongue
 - C08.8 Overlapping lesion of major salivary glands
 - C14.8 Overlapping lesion of lip, oral cavity, and pharynx

NAACCI





Pharynx Schemas CS v02.04 Nasopharynx Nasopharynx (C11.0 - C11.9) Oropharynx Base of Tongue and Lingual Tonsil (C01.9, C02.4) Soft Palate and Uvula (C05.1-C05.2) Tonsil & Oropharynx (C09.0 - C09.9, C10.0, C10.2 - C10.9) Pharyngeal Tonsil (C11.1)

Pharynx Schemas CS v02.04

- Hypopharynx
 - Pyriform Sinus, Hypopharynx, Laryngopharynx (C12.9, C13.0 C13.9)
- Pharynx NOS
 - Pharynx, NOS, and Overlapping Lesion of Lip, Oral Cavity, and Pharynx (C14.0 - C14.8)

NAACCR

Pharynx Schemas CS v02.04

Melanoma

- Melanoma Nasopharynx (C11.0 C11.9)
- Melanoma Base of Tongue and Lingual Tonsil (C01.9, C02.4)
- Melanoma Soft Palate and Uvula (C05.1-C05.2)
- Melanoma Tonsil & Oropharynx (C09.0 C09.9, C10.0, C10.2 - C10.9)
- Melanoma Pyriform Sinus, Hypopharynx, Laryngopharynx (C12.9, C13.0 - C13.9)
- Melanoma Pharynx, NOS, and Overlapping Lesion of Lip, Oral Cavity, and Pharynx (C14.0 - C14.8)

NAACCR²

CS Tumor Size

	Code	Description		
(000	No mass/tumor found		
l	001-988	001-988 mm (Exact size to nearest mm)		
1	989	989 mm or larger		
	990	Microscopic focus or foci and no size given		
	991	Less than 1 cm		
	992	Less than 2 cm OR greater than 1 cm OR between 1 cm and 2 cm		
п		Stated as T1 with no other information on size*		

*Oropharynx schemas; Pharynx NOS schema

CS Tumor Size

Code	Description				
993	Less than 3 cm OR greater than 2 cm OR between 2 cm and 3 cm				
994	Less than 4 cm OR greater than 3 cm OR between 3 cm and 4 cm Stated as T2 with no other information on size*				
995	Less than 5 cm OR greater than 4 cm OR between 4 cm and 5 cm				
996	Greater than 5 cm				
999	Unknown				
*Oropharynx schemas; Pharynx NOS schema					

CS Extension: Nasopharynx

- Code 000: In situ
- Codes 105-510: Confined to nasopharynx or extends to oropharynx and/or nasal cavity without parapharyngeal extension
- Codes 555-590: Parapharyngeal extension
- Codes 605-645: Involves bony structures of skull base and/or paranasal sinuses
- Codes 710-810: Intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or extension to infratemporal fossa/masticator space

NAACC

CS Extension: Oropharynx Base of Tongue & Lingual Tonsil

- Code 000: In situ
- Codes 100-620: T category based on tumor size
- Codes 640-650: Extends to lingual surface of epiglottis
- Codes 710-775: Moderately advanced local disease
 - Invades larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible
- Codes 780-810: Very advanced local disease
 - Invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull base, or encases carotid artery

CS Extension: Oropharynx Soft Palate & Uvula

- Code 000: In situ
- Codes 100-600: T category based on tumor size
- Codes 640-645: Extends to lingual surface of epiglottis
- Codes 650-735: Moderately advanced local disease
 - Invades larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible
- Codes 740-810: Very advanced local disease
 - Invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull base, or encases carotid artery

NAACCR

CS Extension: Oropharynx Tonsil & Oropharynx

- Code 000: In situ
- Codes 150-520: T category based on tumor size
- Codes 530-540: Extends to lingual surface of epiglottis
- Codes 610-705: Moderately advanced local disease
 - Invades larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible
- Codes 708-810: Very advanced local disease
 - Invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull base, or encases carotid artery

NAACCR²

CS Extension: Oropharynx Pharyngeal Tonsil

- Code 000: In situ
- Codes 105-566: T category based on tumor size
- Codes 568-575: Extends to lingual surface of epiglottis
- Codes 610-665: Moderately advanced local disease
 - Invades larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible
- Codes 710-810: Very advanced local disease
 - Invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, skull base, or encases carotid artery

CS Extension: Hypopharynx

- Code 000: In situ
- Code 100: Limited to 1 subsite of hypopharynx
- Code 200; 400-450: Invades more than 1 subsite of hypophyarnx or an adjacent site without fixation of hemilarynx
- Codes 550-560: Fixation of hemilarynx or extension to esophagus
- Codes 600-638: Moderately advanced local disease
 - Invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, or central compartment soft tissue
- Codes 640-810:Very advanced local disease
 - Invades prevertebral fascia, encases carotid artery, or involves mediastinal structures

NAACCR

CS Extension: Pharynx NOS

- Code 000: In situ
- Codes 100-300: Confined to site of origin
- Codes 400-600: More than 1 region of pharynx involved or extension to adjacent organs or structures
- Code 800: Further contiguous extension

NAACCR²

Pop Quiz

- Tonsillectomy: Squamous cell carcinoma, 2.5 cm tumor, confined to tonsil; pT2.
- What is the code for CS Extension?
 - 150: Invasive tumor confined to 1 of the following subsites: Anterior wall including vallecula; 1 lateral wall; posterior wall
 - 310: Stated as T2 with no other information on extension
 - 999: Unknown

CS Lymph Nodes: All Pharynx Schemas

- Includes lymph nodes defined as Levels I-VII and Other by AJCC
- Other information about regional lymph node involvement coded in SSF 1, 3-9
- Consider nodes ipsilateral if laterality not specified or midline nodes
- If nodes described as supraclavicular, determine if Level IV or Level V
 - Code as Level V if level cannot be determined

NAACCE

CS Lymph Nodes: Nasopharynx

- Choose code that specifies
 - Specific nodes involved
 - Bilateral, contralateral, or not stated if bilateral or contralateral

NAACCR²

CS Lymph Nodes: Oropharynx & Hypopharynx

- Choose code that specifies
 - Specific nodes involved
 - Single or multiple nodes involved
 - Bilateral, contralateral, or not stated if bilateral or contralateral

NAACCE

CS Lymph Nodes: Pharynx NOS

- Choose code that specifies
 - Specific nodes involved

NAACCR

Pop Quiz

- Squamous cell carcinoma of nasopharynx with involvement of bilateral Level II lymph nodes and left Level IV lymph nodes.
- What is the code for CS Lymph Nodes?
 - 105: Unilateral positive Level II lymph nodes
 - 130: Unilateral positive Level IV lymph nodes
 - 405: Positive bilateral nodes listed in code 105
 - 430: Positive bilateral nodes, any listed in code 130
 WITH or WITHOUT nodes listed in code 105 or 115

NAACCR²

CS Mets at DX: All Pharynx Schemas

- Record distant metastasis including lymph nodes and/or distant sites at the time of diagnosis
- Code involvement of mediastinal lymph nodes, excluding superior mediastinal lymph nodes, in CS Mets at DX
- Code involvement of supraclavicular and transverse cervical lymph nodes in CS Lymph Nodes

NAACCE

SSF1: Size of Lymph Nodes

- Code largest diameter of involved regional nodes
- Clinical assessment
 - Code size as described in clinical or radiographic exam
- Pathologic assessment
 - Code size as described on pathology report

NAACCR

Pop Quiz

- Squamous cell carcinoma of nasopharynx. Per physical exam cervical nodes involved with size of largest involved node 3 cm. CT scan of neck showed nasopharynx tumor and largest involved cervical node 1.8 cm.
- What is the code for SSF1?
 - -018
 - -030
 - 999

NAACCR²

SSF3 – SSF6: Lymph Node Levels for Head and Neck


- SSF 3: Levels I-III
- SSF 4: Levels IV, V, retropharyngeal nodes
- SSF 5: Levels VI, VII, facial nodes
- SSF 6: Parapharyngeal, parotid, and suboccipital/retroauricular nodes

NAACCE

SSF3 - SSF6: Node Levels

- Code presence or absence of node involvement
- One digit used to represent lymph nodes of a single level
- If you only have information about one level of lymph nodes, code all other lymph levels as 0
- If you know regional lymph nodes are positive but the lymph node level is unknown, code 000
- If no lymph nodes are involved clinically or pathologically, code 000

NAACCR²



SSF7: Upper and Lower Cervical Node Levels • Upper Cervical Nodes - Level I, II, III, VA - Facial, Parotid, Parapharyngeal, Retropharyngeal, Retropharyngeal, Retroauricular, and Suboccipital • Lower Cervical Nodes - Level IV, VB, VII • Level VI can be either upper or lower

Pop Quiz

- Squamous cell carcinoma of nasopharynx with involvement of bilateral Level II lymph nodes, left Level IV lymph nodes, and bilateral Level V nodes.
- What is the code for SSF7?
 - 010: Upper level lymph nodes involved
 - 020: Lower level lymph nodes involved
 - 030: Upper & lower level lymph nodes involved
 - 040: Unknown level lymph nodes involved

NAACCI

NAACCR

When tumor with a lymph nodes extends beyond the wall of the node into the perinodal fat. Curicul Republic Curicul Repu

Extracapsular Extension, Lymph Nodes SSF8: Clinically SSF9: Pathologically • Physical Exam Macroscopic Fixed May be described in gross dissection - Matted Takes priority over Imaging microscopic description - Amorphous • Microscopic Spiculated margins May not be evident in Stranding into perinodal gross exam soft tissue Described in microscopic section of path report

Pop Quiz

- CT scan of neck: Oropharyngeal tumor, most likely malignant, malignant cervical node adenopathy.
- Laryngoscopy & biopsy: Squamous cell carcinoma of oropharynx, tumor greater than 3 cm.
- Referred to oncology for chemotherapy.

NAACCR²

Pop Quiz

- · What is the code for SSF8?
 - 000: No regional nodes involved clinically
 - 010: Regional nodes involved clinically, no extracapsular extension clinically
 - 030: Regional nodes involved clinically, unknown if extracapsular extension
 - 998: No clinical exam of regional lymph node

NAACCR²

Pop Quiz

- What is the code for SSF9?
 - 000: No regional lymph nodes involved pathologically
 - 010: Regional lymph nodes involved pathologically, no extracapsular extension pathologically
 - 050: Regional nodes involved pathologically, unknown if extracapsular extension
 - 998: No histopathologic exam of regional nodes

SSF10: Human Papilloma Virus (HPV) **Status**


- HPV plays a result in pathogenesis of some cancers
- Results of HPV testing on cancer tissue
- Highest risks: Types 16 and 18
- Other high risk: multiple types noted in SSF table
- HPV vaccine designed to protect against types 16, 18, 6, 11
- Codes 000 or 060
 - If test reports only negative or positive for high-risk HPV

SSF25: Schema Discriminator Nasopharynx/Pharyngeal Tonsil

Code	Description	Schema
010	Posterior wall of nasopharynx Posterior wall of nasopharynx NOS	Nasopharynx
020	Adenoid Pharyngeal tonsil Nasopharyngeal tonsil	PharyngealTonsil
981	Nasopharynx cases coded to C11.0, C11.2, C11.3, C11.8, C11.9	Nasopharynx

NAACCR²







Unresectable Disease Unresectable Physician does not feel they can remove all gross disease Surgery will not achieve localized control of the disease Inoperable Patient that is a surgical candidate, but surgery is not done due to comorbid conditions


Salvage Surgery

 Patients that do not have a total response to chemotherapy and/or radiation may have salvage therapy to remove any residual cancer

NAACCR


Surgery

- 30 Pharyngectomy, NOS
 - 31 Limited/partial pharyngectomy; tonsillectomy, bilateral tonsillectomy
 - 32 Total pharyngectomy



Surgery

- 40 Pharyngectomy WITH laryngectomy OR removal of contiguous bone tissue, NOS (does NOT include total mandibular resection)
 - 41 WITH Laryngectomy (laryngopharyngectomy)
 - 42 WITH bone
 - 43 WITH both 41 and 42



Surgery So Radical pharyngectomy (includes total mandibular resection), NOS S1 WITHOUT laryngectomy S2 WITH laryngectomy

Neck Dissection

- Comprehensive neck dissection
 - Removal of level I-V lymph nodes
- Selective neck dissection for pharyngeal primaries
 - Neck dissection based on the understood common pathways of spread for head and neck cancers.
 - Removal of II-IV and VI if required

NAACCR²

Neck Dissection

- Selective neck dissection
 - Neck dissection based on the understood common pathways of spread for head and neck cancers.
 - Patient who receive a selective neck dissection are generally clinically node negative.

Radiation

- Radiation Treatment Volume
 - Head and neck (05)
- Regional Treatment Modality
 - Primary tumors and gross adenopathy generally receive 66-74 Gy at 2Gy per day
 - Patients receiving hyperfractionation may receive 80-81 Gy (80.3 at 1.15 Gy twice daily)
- IMRT dose painting
 - Different dose levels to different structures within the same treatment fraction

NAACCR

Chemotherapy

- Primary systemic therapy plus radiation for squamous cell carcinomas
 - Cisplatin
 - 5fu/hydroxyurea
 - Cisplatin/paclitaxel
 - Cisplatin/infusional 5fu
 - Carboplatin/infusional 5fu
 - Cetuximab

NAACCR²

Nasopharynx

- Early stage tumors are primarily treated with radiation therapy.
 - This may be done in combination with a platinum based chemotherapy.
- Later stage tumors are primarily treated with radiation combination of chemotherapy and radiation.

Oropharynx

- T1 or T2 with N0 or N1 (tumor less the 4cm and no more than 1 positive ipsilateral node)
 - Definitive radiation therapy or
 - Excision of primary with or without a unilateral or bilateral neck dissection or
 - Radiation therapy and systemic therapy (usually only when N1).

NAACCI

Oropharynx

- T3 or T4 (tumor greater than 4cm or tumor invades specific structures surrounding the oropharynx) and N0 (node negative).
 - Concurrent systemic therapy and radiation therapy or
 - Surgery or
 - Induction chemotherapy followed by concurrent chemotherapy and radiation or
 - Multimodality clinical trials

NAACCR²

Oropharynx

- T3-T4 (tumor greater than 4cm or tumor invades specific structures surrounding the oropharynx) and node positive or any T and N2-N3 (lymph node greater than 3cm or more than one lymph node involved)
 - Concurrent systemic therapy and radiation therapy.
 - Induction chemotherapy followed by chemotherapy and radiation therapy
 - Surgery to the primary and neck dissection
 - Multimodality clinical trial

Hypopharynx

- Early T stage (T1 or a small T2) with negative lymph nodes.
 - Definitive radiation therapy
 - Partial Laryngopharyngectomy with selective neck dissection.

NAACCI

Hypopharynx

- T1 with positive nodes or T2 or T3 with any N.
 - Induction chemotherapy
 - Laryngopharyngectomy followed by radiation and possibly adjuvant chemotherapy
 - If lymph node negative, then selective node dissection
 - If lymph node positive, then comprehensive neck dissection including level VI
 - Concurrent systemic therapy and radiation therapy.
 - Multimodality clinical trials

NAACCR²

Hypopharynx

- · T4a and any N
 - Surgery and comprehensive neck dissection followed by chemotherapy and radiation or
 - Induction chemotherapy followed by concurrent chemotherapy and radiation of just radiation or
 - Concurrent systemic therapy and radiation therapy.
 - Multimodality clinical trials



Coming up! • 1/10/13 - Bone and Soft Tissue • 2/7/13 - Central Nervous System • Certificate phrase: - Throat Cancer



THANK YOU!	
	NAACCR [*]